•27% risk reduction of a feeding tube for oropharyngeal cancer

•Fewer side effects for the first 3-month post treatment,quicker return to normal life with oropharyngeal cancer

•45% reduction in overall risk of a feeding tube for nasopharyngeal cancer

•Dramatic reduction of negative impact on taste, nausea, and painful changes to the mouth in salivary gland treatment

•44% relative increase of 5-year survival rate for nasal and paranasal sinus cavity cancers

•10% increase of 5-year overall survival rate for stage I-III

•10% increase of 5-year overall survival rate of local cancer control for stage II-III

•15% decrease of distant metastasis of 5-year overall survival rate for stage II-III

•26% reduction in pulmonary toxicity compared to X-ray therapy (IMRT)

•21% risk reduction in the risk of severe, treatment related lymphopenia, particularly in lower esophagus

•3-4-day reduction in average hospital stay after surgery

•88% less radiation dose to the heart for left sided breast cancer

•44% reduction in clinically significant radiation doses to theu lng

•90% of partial breast irradiation cases result in good to excleelnt cosmetic outcomes for 5 years

•Well tolerated – Less than 4% serious side effects (grade 3) in locally advanced breast cancer

•35% relative increase of 5-year overall survival rate for stage II-III

•56% relative reduction in incidences of serious (grade 3) pain with swallowing (esophagitis)

•Up to 4-week reduction in treatment time for select cases

•26–39% risk reduction in secondary malignancies

•31% relative reduction in occurrence of secondary cancers after treatment

•38% relative improvement of 5-year overall survival rate

•60% reduction in the need for nasogastric tube feeding

•50% reduction in the need for nasogastric tube feeding 74% relative reduction in moderate to severe xerostomia(dry mouth)

•35% relative increase of 5-year overall survival rate for stage II-III

•56% relative reduction in serious (grade 3) pain with swallowing (esophagitis)

•Up to 4-week reduction in treatment time for selected cases

•3More than 50% reduction in radiation dose to critical structures including bone marrow

•49–56% relative improvement of tumor control rate

•153% relative improvement of 5-year overall survival rate

•20% improvement of local tumor control rate

•Reduced impact on height and IQ

•Lower risk of secondary tumors

•5% higher of 5-year overall survival rate in intermediate risk

•Patients receiving proton therapy report the highest quality of life compared to surgery, x-ray, or brachytherapy

•35% less radiation to bladder and 59% less radiation to rectum

•42% risk reduction in secondary malignancy

•50% reduction in treatment related bowel frequency and urgency at 2 years

•21% lower of risk in urinary toxicity for 2 years

•25% lower of risk in erective dysfunction for 2 years